Application process is closed.
The OHSAM annual meeting provides a unique opportunity to discuss, debate, and network with colleagues and build new relationships with leading experts in addiction medicine. Members benefit from learning and sharing together, the poster presentations will share clinical or and research work in the field of addiction medicine, and the exhibit hall is a great place to network with colleagues and connect with company representatives whose products and services are designed to help you and your patients.
OHSAM membership will be verified and you will be notified if there are any questions.
If you have not paid your 2023 membership dues, or aren’t sure of your membership status, go to www.asam.org/join.
Your membership in ASAM includes OHSAM membership.
Make your reservations by Sept. 28 for the discounted room rate of $159 plus tax.
Online: Go here to reserve a room online
By phone: Call the Renaissance at 1-833-427-0292 and mention the OHSAM meeting code: Oct2023 for the discount
VIEW THE MEETING AGENDA (subject to change)
Registration / Continental Breakfast / Visit Exhibits
Ted Parran, MD, OHSAM president
Introductions & Moderator
Gregory Boehm, MD, FASAM, OHSAM education committee chair
Treatment for Novel Psychoactive Substances
Michael Weaver, MD, DFASAM, University of Texas Health Science Center at Houston
Patterns of drug use are constantly changing, particularly regarding new psychoactive substances, which can be challenging to identify and treat effectively, especially serious medical and psychiatric complications. This is important for practitioners, as new designer drugs have resulted in multiple deaths, as well as other significant health consequences to users. This session will educate practitioners about several new drug use trends and their health consequences. By attending you should be able to identify emerging psychoactive substances, including kratom, phenibut, synthetic cannabinoids, and others, and discuss treatment of medical and psychiatric complications resulting from use of emerging substances of abuse.
Methamphetamine Addiction Treatment
Michael Weaver, MD, DFASAM, University of Texas Health Science Center at Houston
Methamphetamine use is highly prevalent across the U.S. Use of methamphetamine can lead to serious medical and mental health complications, so people with methamphetamine use disorder are likely to come into contact with the health care system. Recognition of methamphetamine use and awareness of effective treatments in important for healthcare providers. By attending you should be able to discuss problems resulting from use of methamphetamine and compare different behavioral and medication treatments for stimulant use disorder.
Lulu Zhao, MD, FACOG, FASAM, Director of RISE-Moms, University Hospitals Cleveland Medical Center
Cannabis use in America has increased significantly over the past decade, bolstered by increased access and normalization. Ohio is now poised to become the 24th state to legalize adult use of cannabis for recreational purposes. Healthcare providers should expect that pregnant and postpartum women who use cannabis will desire more nuanced and educated conversations regarding their use in this evolving medico-legal landscape. This discussion will review the history of cannabis in America, the most up to date evidence regarding cannabis use in the perinatal period, and social justice aspects of cannabis use during pregnancy and postpartum.
Special Considerations for Treating SUDs in Pregnant and Breastfeeding Patients Layne
A. Gritti, DO, Sweetgrass Psychiatry
For providers who do not regularly manage patients who are pregnant and breastfeeding, these patients can be intimidating due to the special considerations to consider when treating them. This session will present a way to think about approaching these patients and give them the tools to find the answers they need. By attending you should be able to complete a Risk-Risk analysis for a number of medications we commonly use in SUD treatment, and evaluate PLLR labeling.
Break / Visit Exhibits and Scientific Posters
Contraception Essentials for the Addiction Specialist
Zevidah Vickery, MD, MSCI, MetroHealth Medical Center, Case Western Reserve University
As much as 50% of American pregnancies are not planned; evidence shows that women with substance use and use disorders experience mistimed and unintended pregnancy at even higher rates. Pregnancies affected by substance use are at greater risk of poor outcomes such as miscarriage, preterm labor, abruptio placentae, fetal growth restriction and neonatal abstinence syndrome. As with any chronic disease, optimization of maternal health before conception is recommended for pregnancy-capable people with SUD. The addiction specialist, with their trust-worthy non-judgmental care and frequent visits, is uniquely situated to assist these patients with meeting their lifetime reproductive goals. By attending you should be able to describe the unmet need for sexual and reproductive healthcare among SUD patients and develop strategies on ways to meet this need among your own patient panel.
Neonatal Abstinence Syndrome
William Goldman, DO, FABP, Diplomate ABPM, Medical Director, Akron Children’s Hospital Addiction Services
There is an increasing number of babies are born to mothers with opioid-use disorder, which results in drug withdrawal. By attending you should be able to define neonatal abstinence syndrome (NAS), recognize the infant presenting with signs of NAS, develop a management plan and provide guidance regarding home-care and follow up.
Women & Children’s Health Panel Discussion
Drs. Zhao, Gritti, Vickery and Goldman – moderated by Dr. Boehm
Lunch / Visit Exhibits and Scientific Posters
Ohio’s Initiatives to Combat the Opioid Epidemic & Budget and Priorities to Prevent and Address Substance Use Disorders
Lori Criss, Director, Ohio Department of Mental Health & Addiction Services
Ohio Office-based Opioid Treatment (OBOT) Rules Update
James Roach, Esq., Enforcement Attorney, State Medical Board of Ohio
The Changing Landscape of Addictions: Gambling/Gaming Disorder, Treatment, and Recovery
Heather A. Chapman, PhD, ICGC II, BACC, Assistant Chief Psychology Service, Director Gambling Treatment Program, Deputy Director Louis Stokes Cleveland Veterans Addiction Recovery Program
Addictions has always been impacted by accessibility factors. In recent years internet, social media, and mobile technology have created the perfect platform for unprecedented access, that then has significant psychosocial consequences. This presentation will discuss the changing landscape of addictions, highlighting gaming/gambling as process addictions become more prevalent due to these availability factors. Elements of neurobiology will be reviewed, as will treatment considerations. By attending you should be able to list the changes in the concept of what constitutes an addiction and identify strategies for gaming/gambling addictive behavior.
Addressing Barriers & Disparities in Addiction Treatment
Kathleen Alto, PhD, Licensed Clinical Psychologist, MetroHealth
According to SAMHSA 2021 National Survey of Drug Use and Health, 2.6% of people aged 12 and over meet criteria for a substance use disorder in the last year, but only 1.5% of people received treatment in the last year. Certain populations, including racial and ethnic minorities, sexual and gender minorities, and the disabled face experience marked disparities in access to quality addiction treatment. To achieve health equity, it is critical to identify and address unique barriers faced by this population. By attending you should be able to describe disparities in addiction treatment for marginalized populations, including social, cultural, and political influences, name common barriers to substance use disorder treatment for marginalized populations, and identify one barrier in your institution for you to target for potential change.
Screening, Treatment and Pharmacological Clinical Considerations for HCV in Persons with Substance Use
James Hanje, MD, FAASLDO, Ohio Gastroenterology Group and Co-Medical Director for the Comprehensive Liver Center at Ohio Health Kenneth Barga, PharmD, BCPS, BCACP, Ambulatory Hepatology Pharmacist, OhioHealth Comprehensive Liver Program
People who use drugs have a high prevalence of hepatitis C virus (HCV) and other infectious diseases along with significant morbidity associated with drug use, especially when injection drug use is involved. By attending you should be able to identify viral and bacterial infections associated with injection drug use, explain the differences between the disease expression and treatment of Hepatitis A and B, and develop actions you could take to integrate HIV and HCV education into your opioid safety efforts.
HCV Panel Discussion
Poster Awards / Business Meeting / Adjourn
- AbbVie Hepatology
- AmeriHealth Caritas Ohio
- Aware Recovery Care
- BrightView Healthcare
- Buckeye Health Plan
- CVS/Aetna OhioRise
- Genoa Healthcare Pharmacy
- Gilead Sciences
- Hep C Cure Squad
Powered by Central Outreach Wellness Center
- Mallinckrodt Pharmaceuticals
- Molina Healthcare
- Ohio Mental Health and Addiction Services
- Orexo US, Inc.
- Recovery Resources
- St. Matthews Pharmacy
- United Healthcare
- US WorldMeds
Continuing Medical Education
AMA PRA Category 1™ – ACCME Accreditation:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American Society of Addiction Medicine (ASAM) and the Ohio Society of Addiction Medicine. The American Society of Addiction Medicine is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation:
The American Society of Addiction Medicine designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credit (s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AOA 1-A credit:
The Ohio University Heritage College of Osteopathic Medicine designates this program for a maximum of 6.25 credits of AOA Category 1-A credit and will report the CME and specialty credits commensurate with the extent of the physician’s participation in this activity. This program qualifies for AOA Category 1-A credit under an exemption approved by the “Bureau of Osteopathic Education of the American Osteopathic Association.”
American Board of Preventive Medicine:
The American Board of Preventive Medicine (ABPM) has approved this activity for 6.25 credits towards ABPM MOC Part II requirements.
American Board of Addiction Medicine:
Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.
MATE Act CME Requirement
Attendance at this meeting meets the new MATE Act CME requirement. Per the rules, trainings on the treatment and management of patients with opioid or other substance use disorders can count towards a practitioner meeting this requirement.
Continuing Education Credits:
Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.